About the Study

For adults with inadequately-controlled symptoms of schizophrenia

The goal of this study is to evaluate the efficacy, safety, and tolerability of adjunctive KarXT compared with placebo in the treatment of participants with inadequately-controlled symptoms of schizophrenia. This study is sponsored by Karuna Therapeutics Inc.

Length of Study:  About 11 Weeks Total : 8 Visits

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18 – 59 years old
• have been diagnosed with schizophrenia
• are currently taking medication for schizophrenia
• have a reliable informant/study partner who can physically be present for the beginning of the trial.

If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.